Gerald Chi Selected Research

betrixaban

1/2021	Extended Thromboprophylaxis With Betrixaban or Rivaroxaban for Acutely Ill Hospitalized Medical Patients: Meta-Analysis of Prespecified Subgroups.
4/2019	Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial.
1/2019	Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy.
11/2018	Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.
1/2018	Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial.
1/2018	Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial).
1/2018	Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients.
1/2018	Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy.
12/2017	Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial.
7/2017	Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gerald Chi Research Topics

Disease

15	Venous Thromboembolism 01/2021 - 01/2015
10	Hemorrhage 01/2021 - 01/2017
7	Venous Thrombosis (Deep-Vein Thrombosis) 01/2021 - 01/2015
6	Acute Coronary Syndrome 03/2022 - 05/2016
6	Myocardial Infarction 01/2022 - 01/2016
6	Thrombosis (Thrombus) 01/2019 - 05/2016
6	Atrial Fibrillation 10/2018 - 01/2017
5	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 04/2018
5	COVID-19 12/2021 - 08/2020
5	Pulmonary Embolism 01/2021 - 01/2015
5	Stroke (Strokes) 11/2018 - 05/2016
4	Inflammation (Inflammations) 07/2019 - 05/2018
3	Heart Failure 01/2020 - 01/2017
2	Atherosclerotic Plaque (Atheroma) 01/2022 - 01/2021
2	Ischemia 01/2018 - 01/2016
2	Ischemic Stroke 01/2017 - 01/2017
1	Brain Ischemia (Cerebral Ischemia) 01/2022
1	Neoplasms (Cancer) 01/2022
1	Pulmonary Edema 01/2022
1	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 01/2022
1	Infections 12/2021
1	Atherosclerosis 01/2021
1	Chest Pain (Chest Pains) 01/2020
1	Pregnancy Complications 01/2019
1	Critical Illness (Critically Ill) 01/2019
1	Renal Insufficiency (Renal Failure) 01/2019
1	Malocclusion (Crossbite) 09/2018
1	Congenital Abnormalities (Deformity) 09/2018
1	Thrombophilia 05/2018
1	Diabetic Nephropathies (Diabetic Nephropathy) 05/2018
1	ST Elevation Myocardial Infarction 01/2016
1	Infarction (Infarctions) 01/2016
1	Reperfusion Injury 01/2016

Drug/Important Bio-Agent (IBA)

12	fibrin fragment D (D-dimer)IBA 07/2021 - 01/2015
12	betrixabanIBA 01/2021 - 01/2017
8	Enoxaparin (Lovenox)FDA LinkGeneric 01/2021 - 01/2017
7	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2016
6	AnticoagulantsIBA 01/2021 - 01/2018
5	RivaroxabanIBA 01/2021 - 01/2017
4	Vitamin K FDA Link 10/2018 - 01/2017
2	Hemoglobins (Hemoglobin)IBA 01/2022 - 01/2018
2	Troponin IIBA 01/2022 - 01/2016
2	Biological ProductsIBA 01/2021 - 12/2018
2	omega-Chloroacetophenone (Mace)IBA 01/2020 - 04/2018
2	C-Reactive ProteinIBA 01/2019 - 11/2017
2	cupric sulfide (CuS)IBA 12/2018 - 01/2018
2	Warfarin (Coumadin)FDA LinkGeneric 10/2018 - 01/2018
2	Factor Xa InhibitorsIBA 10/2018 - 01/2017
2	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 01/2018 - 01/2017
1	LDL CholesterolIBA 03/2022
1	LipidsIBA 01/2022
1	CholesterolIBA 01/2022
1	TroponinIBA 01/2022
1	ApoproteinsIBA 01/2022
1	MDCO-216IBA 01/2022
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2022
1	CSL112IBA 01/2022
1	trans-crotonin (CTN)IBA 01/2022
1	CER-001IBA 01/2022
1	Azithromycin (Zithromax)FDA LinkGeneric 12/2021
1	Chloroquine (Aralen)FDA LinkGeneric 12/2021
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 12/2021
1	Interleukin-27 (Interleukin 27)IBA 01/2021
1	HDL CholesterolIBA 01/2021
1	Illicit Drugs (Recreational Drugs)IBA 07/2019
1	Serum AlbuminIBA 01/2019
1	AlbuminsIBA 01/2019
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2019
1	Therapeutic UsesIBA 10/2018
1	AntithrombinsIBA 10/2018
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 05/2018
1	InterleukinsIBA 05/2018
1	DABIIBA 01/2018
1	Pharmaceutical PreparationsIBA 01/2018
1	hemoglobin ASIBA 01/2018
1	Brain Natriuretic Peptide (Natrecor)FDA Link 11/2017
1	pro-brain natriuretic peptide (1-76)IBA 11/2017
1	Natriuretic PeptidesIBA 01/2017
1	vorapaxarIBA 05/2016
1	MB Form Creatine KinaseIBA 01/2016
1	arginyl- 2,'6'- dimethyltyrosyl- lysyl- phenylalaninamideIBA 01/2016

Therapy/Procedure

11	Therapeutics 03/2022 - 01/2017
5	Percutaneous Coronary Intervention 01/2020 - 05/2016
3	Stents 05/2018 - 05/2016
2	Patient Readmission 01/2018 - 01/2017
1	Artificial Respiration (Mechanical Ventilation) 12/2021
1	Denervation 01/2020
1	Drug Therapy (Chemotherapy) 11/2018
1	Off-Label Use 10/2018
1	Osteotomy 09/2018
1	Vascular Closure Devices 01/2018